Article: Not only dopamine D 2 receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleNot only dopamine D 2 receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia
AuthorsWang, D2
Wong, HK2
Zhang, L4
McAlonan, GM1
Wang, XM3
Sze, SCW2
Feng, YB2
Zhang, ZJ2
KeywordsAntipsychotics
D 2 receptors
Dopamine
Herbal medicine
Hyperprolactinemia
Peony-Glycyrrhiza Decoction (PGD)
Issue Date2012
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/pnpbp
CitationProgress In Neuro-Psychopharmacology And Biological Psychiatry, 2012, v. 39 n. 2, p. 332-338 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.pnpbp.2012.07.005
AbstractClinical studies have demonstrated the effectiveness of an herbal preparation called Peony-Glycyrrhiza Decoction (PGD) in alleviating antipsychotic-induced hyperprolactinemia (hyperPRL). In the present study, we further examined the pharmacological action of PGD on prolactin (PRL) secretion using in vitro and in vivo models, with specific attention to the role of dopaminergic mediators and other sex hormones. Treatment with PGD at 1-5mg/ml significantly suppressed PRL secretion and synthesis in MMQ cells, a model of hyperPRL derived from pituitary adenoma cells. The suppressive effects were completely abolished by pretreatment with 10μM haloperidol, a dopamine D 2 receptor antagonist. Consistent with a D 2-action, PGD did not affect PRL in rat pituitary lactotropic tumor-derived GH3 cells that lack the D 2 receptor expression but significantly increased the expression of D 2 receptors and dopamine transporters (DAT) in PC12 cells. In a rat model of hyperPRL, produced by repeated injection of the dopamine blocker metoclopramide (MCP), chronic PGD (2.5-10g/kg daily) significantly reduced elevated serum PRL. The reduction in magnitude was similar to that elicited by bromocriptine (BMT), a dopamine D 2 receptor agonist currently used for treatment of hyperPRL. Neither PGD nor BMT altered serum estradiol, but PGD reversed decreased serum progesterone to control level, whereas BMT did not. These results indicate that the anti-hyperPRL effects of PGD are associated not only with D 2 receptor and DAT modulation, but also with a normalization of other sex hormone dysfunction. This experimental evidence supports clinical use of PGD as an effective treatment of antipsychotic-induced hyperPRL. © 2012 Elsevier Inc.
ISSN0278-5846
2011 Impact Factor: 3.247
2011 SCImago Journal Rankings: 0.172
DOIhttp://dx.doi.org/10.1016/j.pnpbp.2012.07.005
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorWang, D
dc.contributor.authorWong, HK
dc.contributor.authorZhang, L
dc.contributor.authorMcAlonan, GM
dc.contributor.authorWang, XM
dc.contributor.authorSze, SCW
dc.contributor.authorFeng, YB
dc.contributor.authorZhang, ZJ
dc.date.accessioned2012-08-16T05:57:39Z
dc.date.available2012-08-16T05:57:39Z
dc.date.issued2012
dc.description.abstractClinical studies have demonstrated the effectiveness of an herbal preparation called Peony-Glycyrrhiza Decoction (PGD) in alleviating antipsychotic-induced hyperprolactinemia (hyperPRL). In the present study, we further examined the pharmacological action of PGD on prolactin (PRL) secretion using in vitro and in vivo models, with specific attention to the role of dopaminergic mediators and other sex hormones. Treatment with PGD at 1-5mg/ml significantly suppressed PRL secretion and synthesis in MMQ cells, a model of hyperPRL derived from pituitary adenoma cells. The suppressive effects were completely abolished by pretreatment with 10μM haloperidol, a dopamine D 2 receptor antagonist. Consistent with a D 2-action, PGD did not affect PRL in rat pituitary lactotropic tumor-derived GH3 cells that lack the D 2 receptor expression but significantly increased the expression of D 2 receptors and dopamine transporters (DAT) in PC12 cells. In a rat model of hyperPRL, produced by repeated injection of the dopamine blocker metoclopramide (MCP), chronic PGD (2.5-10g/kg daily) significantly reduced elevated serum PRL. The reduction in magnitude was similar to that elicited by bromocriptine (BMT), a dopamine D 2 receptor agonist currently used for treatment of hyperPRL. Neither PGD nor BMT altered serum estradiol, but PGD reversed decreased serum progesterone to control level, whereas BMT did not. These results indicate that the anti-hyperPRL effects of PGD are associated not only with D 2 receptor and DAT modulation, but also with a normalization of other sex hormone dysfunction. This experimental evidence supports clinical use of PGD as an effective treatment of antipsychotic-induced hyperPRL. © 2012 Elsevier Inc.
dc.description.naturelink_to_subscribed_fulltext
dc.identifier.citationProgress In Neuro-Psychopharmacology And Biological Psychiatry, 2012, v. 39 n. 2, p. 332-338 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.pnpbp.2012.07.005
dc.identifier.citeulike11583355
dc.identifier.doihttp://dx.doi.org/10.1016/j.pnpbp.2012.07.005
dc.identifier.epage338
dc.identifier.hkuros205007
dc.identifier.hkuros208633
dc.identifier.issn0278-5846
2011 Impact Factor: 3.247
2011 SCImago Journal Rankings: 0.172
dc.identifier.issue2
dc.identifier.pmid22796279
dc.identifier.scopuseid_2-s2.0-84867024470
dc.identifier.spage332
dc.identifier.urihttp://hdl.handle.net/10722/159823
dc.identifier.volume39
dc.languageeng
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/pnpbp
dc.publisher.placeUnited States
dc.relation.ispartofProgress in Neuro-Psychopharmacology and Biological Psychiatry
dc.relation.referencesReferences in Scopus
dc.subjectAntipsychotics
dc.subjectD 2 receptors
dc.subjectDopamine
dc.subjectHerbal medicine
dc.subjectHyperprolactinemia
dc.subjectPeony-Glycyrrhiza Decoction (PGD)
dc.titleNot only dopamine D 2 receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia
dc.typeArticle
Author Affiliations
  1. King's College London
  2. The University of Hong Kong Li Ka Shing Faculty of Medicine
  3. National Institute of Nursing Research
  4. National Institute on Alcohol Abuse and Alcoholism